Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 5/20 | 0.34 |
| ▸ | AURKA | O14965 | 3/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903244 | 0.88 | TACR3 (0.35) | TACR3PDE2ACHEK1AKT1AURKA | |
| SCHEMBL1906672 | 0.88 | TACR3 (0.38) | TACR3PDE2ACHEK1AKT1AURKA | |
| SCHEMBL14118957 | 0.87 | TACR3 (0.41) | TACR3PDE2ACHEK1AKT1SCN9A | |
| SCHEMBL1907564 | 0.87 | TACR3 (0.37) | TACR3PDE2ACHEK1AKT1SCN9A | |
| SCHEMBL1905535 | 0.85 | AURKA (0.41) | TACR3PDE2ACHEK1AKT1AURKA | |
| SCHEMBL1900984 | 0.84 | AKT1 (0.40) | TACR3PDE2AAKT1AKT2SCN9A | |
| SCHEMBL1903041 | 0.84 | AKT1 (0.38) | TACR3PDE2AAKT1SCN9A | |
| SCHEMBL1904589 | 0.84 | SCN9A (0.37) | TACR3PDE2AAKT1SCN9A | |
| SCHEMBL14118904 | 0.84 | TACR3 (0.37) | TACR3PDE2ACHEK1AKT1AURKA | |
| SCHEMBL1903118 | 0.84 | TACR3 (0.35) | TACR3PDE2ACHEK1AKT1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | TACR3 3761/4885PDE2A 2363/4885CHEK1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.